Instructions for Cytoflavin (Riboflavin, Nicotinamide, Inosine, Succinic acid)
Release form
tab, intestinal-soluble shell: 50 or 100 pcs
Description:
Tablets covered with a intestinal-soluble shell of red color, round, double-convex; two layers are visible on the cross section; The core of tablets is yellow to yellow-orange.
1 tab.
succinic acid 300 mg
inosine (riboxin) 50 mg
Nicotinamide 25 mg
Riboflavin (in the form of sodium phosphate Riboflavin) 5 mg
Auxiliary substances: povidone K30 - 8.1 mg, calcium stearate - 3.9 mg, hypromellose - 3.6 mg, polysorbate 80 - 0.4 mg.
Intestinal-soluble shell composition: The copolymer of methacrylic acid and ethylacrylate [1:1] - 29.02 mg, propylene glycol - 2.91 mg, the dye azorubin (carmuazine) (E122) - 0.07 mg.
Release form
Solution for injection
Composition
Composition Solution for in/in injection transparent, yellow. 1 l amber acid 100 g inosine (riboxin) 20 g Nicotinamide 10 g Riboflavin sodium phosphate (Riboflavin) 2 g Auxiliaries: meglumine (N-methylglucamine) - 165 g, sodium hydroxide - 34 g, water d/i - up to one l.
To control the first opening, the side valves of the packs can be glued on both sides with labels.
ATC codes
N07XX Other drugs for the treatment of diseases of the nervous system
Clinical-pharmacological groups / Group affiliation
A drug that improves brain metabolism
Active substance
- Nicotinamide
- inozin
- succinic acid
- Riboflavin (in the form of sodium phosphate Riboflavin)
Pharmacotherapy group
Metabolic agent
Storage Conditions
The drug should be stored in a place inaccessible to children, protected from light at a temperature not higher than 25 ° C.
Best before date
Shelf life is 3 years. Do not apply after the expiry date indicated on the package.
Testimony:
- As part of complex therapy in adults:
- the effects of a brain infarction;
- cerebrovascular diseases (cerebral atherosclerosis,
- hypertensive encephalopathy
- Neurasthenia increased irritability,
- tiredness, loss of capacity for prolonged mental and physical exertion).
How to take the drug:
The drug Cytoflavin is taken in 2 tabs. 2 times / day at an interval of 8-10 hours. It is recommended to take Cytoflavin® in the morning and in the afternoon, not later than 18 hours.
Tablets should be taken at least 30 minutes before eating, not chewing, drinking water (100 ml).
The duration of treatment is 25 days. You can assign a second course at least 1 month.
Overdose:
To date, no overdose of Cytoflavin® has been identified.
Application for kidney disorders
With caution, use the drug for nephrolithiasis.
Terms of Sale
The drug is prescription.
Use in children
It is contraindicated in children and adolescents under 18 years of age.
Nosology (ICD codes)
F48.0
Neurasthenia
G92
Toxic encephalopathy
G93.4
Encephalopathy unrefined
I63
Brain infarction
I67.2
Cerebral atherosclerosis
I67.4
Hypertensive encephalopathy
I69
Effects of cerebrovascular disease
R45.4
Irritability and anger
R53
Malaise and fatigue
Z73.0
Overwork
Z73.3
Stress conditions not classified in other headings (physical and mental stress)
Pharmacokinetics:
In the case of infusion at a rate of about 2 ml/min (in terms of undiluted Cytoflavin), amber acid and inosine are disposed of almost instantaneously and are not detected in the blood plasma. Inosine is metabolized in the liver to form hypoxanthine and then oxidized to uric acid. In small numbers it is released by the kidneys. Nicotinamide is rapidly distributed throughout the tissue, penetrates the placental barrier, and is released with breast milk. It is metabolized in the liver to form Nicotinamide-N-methylNicotinamide, excreted by the kidneys.
T1/2 of plasma is about 1.3 h, Vss about 60 l, total clearance about 0.6 l/min. Riboflavin is distributed unevenly: The greatest amount is in myocardium, liver, kidneys. T1/2 of plasma is about 2 h, Vss about 40 l, total clearance about 0.3 l/min. It penetrates the placental barrier and is excreted with breast milk. Binding to plasma proteins is 60%. Excreted by the kidneys, partly as a metabolite; when used in high doses, preferably in the unchanged form.
